BioSpace News Archive

Fresenius Medical Care today announced the presentation of nearly 40 company-affiliated research abstracts at the 61st European Renal Association (ERA) Congress, taking place May 23-26, 2024, in Stockholm, Sweden and virtually.

Edgewood Oncology today announced that the first two patients with metastatic breast cancer were treated with BTX-A51, a multi-specific kinase inhibitor of casein kinase 1 alpha (CK1α) and cyclin-dependent kinases 7 and 9 (CDK7 and CDK9), that synergistically targets master regulators of cancer.

Somite Therapeutics, a tech-bio company harnessing big data and AI to pioneer novel cell replacement therapies, is thrilled to announce the addition of Prof. Jay Shendure as its newest Scientific Co-Founder.

According to latest study, the U.S. mRNA therapeutics market size was worth around USD 5.10 billion in 2023 and is predicted to grow around USD 12.18 billion by 2033 with a compound annual growth rate (CAGR) of roughly 9.1% between 2024 and 2033.

Leiden, the Netherlands, May 21, 2024: Pharming Group N.V. announces that at its Annual General Meeting of Shareholders held , all proposals were approved.

Surgical teams at NYU Langone Health performed the world’s first genetically modified pig kidney transplants into a human body in September and November 2021, and then transplanted two pig hearts in the summer of 2022.

Aster Insights, the leading provider of scientific and clinical intelligence for oncology discovery, announced the company and members of the Oncology Research Information Exchange Network® will be presenting at the American Society of Clinical Oncology annual meeting, which will be held May 31 – June 4, in Chicago, IL.

Pierre Fabre Laboratories announce the submission by Atara Biotherapeutics of Tabelecleucel Biologics License Application for treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S FDA.

Incyte announced the expansion of its presence in Delaware with the acquisition of two buildings at 1100 North King Street and 1100 North French Street in downtown Wilmington.

Modular Medical, Inc. (NASDAQ:MODD) (“Modular Medical” or the “Company”) will participate in a webcasted presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2024 Investor Conference, taking place virtually on Thursday, May 30, 2024.